시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 시신경척수염 스펙트럼 장애 시장 보고서(2025년)
Neuromyelitis Optica Spectrum Disorder Global Market Report 2025
상품코드 : 1730964
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,151,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,891,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,632,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

시신경척수염 스펙트럼 장애 시장 규모는 향후 몇 년간 강력한 성장이 예상될 예정입니다. 또한 NMOSD 치료제의 임상시험 증가, 맞춤형 의료에 대한 수요 증가가 견인할 것으로 보입니다.

다발성 경화증(MS)의 유병률 증가는 시신경척수염 스펙트럼 장애 시장의 성장을 가속할 것으로 예측됩니다. 자기 면역 질환입니다. MS의 유병률 증가는 진단 기술의 향상, 환경 요인, 유전적 소인에 기인합니다. MS의 진단 건수가 증가함에 따라 신경학적 자가면역질환에 대한 인식도 높아지고 진단방법의 개선이나 NMOSD와 같은 질환에 대한 이해도 깊어지고 있습니다. 트러스트는 예를 들어, 2024년 5월, 다발성 경화증 트러스트는 영국에서 매년 약 7,100건의 새로운 다발성 경화증 사례가 발생하고 매주 약 135건의 새로운 진단이 이루어진다고 보고했습니다. 따라서, MS의 유병률 증가가 시신경척수염 스펙트럼 장애 시장의 성장에 박차를 가하고 있습니다.

시신경척수염 스펙트럼 장애 시장의 기업은 치료 효과를 높이고 환자의 결과를 개선하기 위해 장시간 작용형 보체 억제제 등의 혁신적인 치료법의 개발에 주력하고 있습니다. 이 치료는 재발을 억제하고 장기적인 질병 관리에 기여합니다. 예를 들어, 2024년 3월, 미국에 본사를 둔 바이오 제약 회사인 알렉시온 제약과 영국에 본사를 둔 제약 회사인 아스트라제네카는 항아쿠아포린-4(AQP4) 항체 양성 성인 NMOSD 치료제로 ULTOMIRIS(라불리주맙-cwvz)를 승인받았습니다. 얼토미리스는 NMOSD 치료제로 승인된 최초이자 유일한 지속형 C5 보체 억제제입니다. 이번 승인은 위약 대비 73주 동안 재발 위험을 98.6% 감소시켰으며, 임상시험 기간 동안 새로운 안전성 문제가 확인되지 않은 임상 3상 CHAMPION-NMOSD 시험에 근거하여 이루어졌습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily affects the central nervous system, focusing on the spinal cord and optic nerves. The condition is characterized by severe inflammation and demyelination (damage to the protective sheath of nerve fibers) in these areas, leading to symptoms such as vision loss, paralysis, and sensory dysfunction.

The primary types of neuromyelitis optica spectrum disorder include NMOSD with aquaporin-4 antibodies and NMOSD without aquaporin-4 antibodies. NMOSD with aquaporin-4 antibodies occurs when the immune system mistakenly attacks nerve fibers, causing inflammation, vision impairment, and paralysis. Diagnosis is made through various methods, including imaging tests, magnetic resonance imaging (MRI), blood tests, and more. Treatment options include C5 protein inhibitors, monoclonal antibodies, plasma exchange therapy, corticosteroids, immunoglobulin therapy, medications, and others. These treatments are distributed through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end-users, including hospitals, specialty clinics, and home care settings.

The neuromyelitis optica spectrum disorder market research report is one of a series of new reports from The Business Research Company that provides neuromyelitis optica spectrum disorder market statistics, including the neuromyelitis optica spectrum disorder industry global market size, regional shares, competitors with the neuromyelitis optica spectrum disorder market share, detailed neuromyelitis optica spectrum disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromyelitis optica spectrum disorder industry. This neuromyelitis optica spectrum disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historical period can be attributed to factors such as the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), greater awareness and early diagnosis, expanding therapeutic options and FDA approvals, growing research and development activities, and an increase in clinical trials for new therapies.

The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period is expected to be driven by rising awareness and early diagnosis, higher healthcare spending, increased investments in research and development, the growing prevalence of autoimmune diseases, more clinical trials for NMOSD therapies, and a rising demand for personalized medicine. Key trends for the forecast period include advancements in precision medicine, increased collaboration and partnerships, technological innovations, the integration of AI and big data in research, and a shift towards home-based treatments.

The rising prevalence of multiple sclerosis (MS) is expected to drive the growth of the neuromyelitis optica spectrum disorder (NMOSD) market. Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of MS is attributed to improved diagnostic techniques, environmental factors, and genetic predisposition. Advancements in medical imaging, such as MRI, have enabled earlier and more accurate diagnoses, contributing to a rise in detected cases. As the number of MS diagnoses increases, there is greater awareness of neurological autoimmune diseases, which has led to improved diagnostic methods and a better understanding of conditions such as NMOSD. For example, in May 2024, the Multiple Sclerosis Trust reported that the UK sees around 7,100 new MS cases annually, with approximately 135 new diagnoses each week. Therefore, the growing prevalence of MS is fueling the growth of the NMOSD market.

Companies in the NMOSD market are focusing on developing innovative treatments, such as long-acting complement inhibitors, to enhance the effectiveness of therapies and improve patient outcomes. Long-acting complement inhibitors are designed to suppress the complement system for extended periods, preventing inflammation and nerve damage in NMOSD. These treatments help reduce relapses and contribute to long-term disease management. For instance, in March 2024, Alexion Pharmaceuticals, a U.S.-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical firm, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive NMOSD. ULTOMIRIS is the first and only long-acting C5 complement inhibitor approved for NMOSD treatment. The approval was based on the Phase III CHAMPION-NMOSD trial, which showed a 98.6% reduction in relapse risk over 73 weeks compared to a placebo, with no new safety concerns identified during the trial.

In October 2023, Amgen, a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition allows Amgen to expand its portfolio in rare and autoimmune diseases, strengthening its position in the NMOSD market with treatments such as UPLIZNA (ibalizumab-con) for adult patients who are anti-aquaporin-4 (AQP4) antibody-positive. Horizon Therapeutics, based in Ireland, specializes in treatments for NMOSD.

Major players in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics.

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuromyelitis optica spectrum disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuromyelitis optica spectrum disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuromyelitis optica spectrum disorder market consists of revenues earned by entities by providing services such as rehabilitation services, patient assistance programs, and intravenous immunoglobulin (IVIG) therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuromyelitis optica spectrum disorder market includes sales of immunosuppressants, corticosteroids, and symptomatic treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuromyelitis optica spectrum disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for neuromyelitis optica spectrum disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuromyelitis optica spectrum disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Neuromyelitis Optica Spectrum Disorder Market Characteristics

3. Neuromyelitis Optica Spectrum Disorder Market Trends And Strategies

4. Neuromyelitis Optica Spectrum Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuromyelitis Optica Spectrum Disorder Growth Analysis And Strategic Analysis Framework

6. Neuromyelitis Optica Spectrum Disorder Market Segmentation

7. Neuromyelitis Optica Spectrum Disorder Market Regional And Country Analysis

8. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market

9. China Neuromyelitis Optica Spectrum Disorder Market

10. India Neuromyelitis Optica Spectrum Disorder Market

11. Japan Neuromyelitis Optica Spectrum Disorder Market

12. Australia Neuromyelitis Optica Spectrum Disorder Market

13. Indonesia Neuromyelitis Optica Spectrum Disorder Market

14. South Korea Neuromyelitis Optica Spectrum Disorder Market

15. Western Europe Neuromyelitis Optica Spectrum Disorder Market

16. UK Neuromyelitis Optica Spectrum Disorder Market

17. Germany Neuromyelitis Optica Spectrum Disorder Market

18. France Neuromyelitis Optica Spectrum Disorder Market

19. Italy Neuromyelitis Optica Spectrum Disorder Market

20. Spain Neuromyelitis Optica Spectrum Disorder Market

21. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market

22. Russia Neuromyelitis Optica Spectrum Disorder Market

23. North America Neuromyelitis Optica Spectrum Disorder Market

24. USA Neuromyelitis Optica Spectrum Disorder Market

25. Canada Neuromyelitis Optica Spectrum Disorder Market

26. South America Neuromyelitis Optica Spectrum Disorder Market

27. Brazil Neuromyelitis Optica Spectrum Disorder Market

28. Middle East Neuromyelitis Optica Spectrum Disorder Market

29. Africa Neuromyelitis Optica Spectrum Disorder Market

30. Neuromyelitis Optica Spectrum Disorder Market Competitive Landscape And Company Profiles

31. Neuromyelitis Optica Spectrum Disorder Market Other Major And Innovative Companies

32. Global Neuromyelitis Optica Spectrum Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromyelitis Optica Spectrum Disorder Market

34. Recent Developments In The Neuromyelitis Optica Spectrum Disorder Market

35. Neuromyelitis Optica Spectrum Disorder Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기